MACROGENICS, INC. Increase (Decrease) in Restructuring Reserve
MACROGENICS, INC. (MGNX) reported Increase (Decrease) in Restructuring Reserve of $0 for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestructuringReserve · last filed 2019-11-06
- MACROGENICS, INC. increase (decrease) in restructuring reserve for the quarter ending 2019-09-30 was $0.00.
- MACROGENICS, INC. increase (decrease) in restructuring reserve for the quarter ending 2019-06-30 was $0.00.
- MACROGENICS, INC. increase (decrease) in restructuring reserve for the quarter ending 2019-03-31 was $0.00.
- MACROGENICS, INC. increase (decrease) in restructuring reserve for the quarter ending 2018-09-30 was $0.00.
- MACROGENICS, INC. increase (decrease) in restructuring reserve for fiscal 2017 was -$1.59M.
- MACROGENICS, INC. increase (decrease) in restructuring reserve for fiscal 2016 was -$2.82M.
- MACROGENICS, INC. increase (decrease) in restructuring reserve for fiscal 2015 was -$3.29M.
- MACROGENICS, INC. increase (decrease) in restructuring reserve for fiscal 2014 was -$1.44M.
| Period end | Increase (Decrease) in Restructuring Reserve 3 month | Increase (Decrease) in Restructuring Reserve 3 month as first filed | Increase (Decrease) in Restructuring Reserve 6 month | Increase (Decrease) in Restructuring Reserve 9 month | Increase (Decrease) in Restructuring Reserve 9 month as first filed | Increase (Decrease) in Restructuring Reserve 12 month | Increase (Decrease) in Restructuring Reserve 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | ||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $0.00 10-Q · filed 2019-07-31 | |||||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-01 | ||||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | -$298.00K 10-Q · filed 2019-11-06 | -$715.00K derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$298.00K 10-Q · filed 2019-07-31 | -$715.00K derived: sum of 3 quarters · filed 2019-07-31 | -$1.12M derived: sum of 4 quarters · filed 2019-07-31 | |||
| 2018-03-31 | -$298.00K 10-Q · filed 2019-05-01 | -$715.00K derived: sum of 2 quarters · filed 2019-05-01 | -$1.12M derived: sum of 3 quarters · filed 2019-05-01 | -$1.51M derived: sum of 4 quarters · filed 2019-05-01 | |||
| 2017-12-31 | -$417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$822.00K derived: sum of 2 quarters · filed 2018-11-07 | -$1.21M derived: sum of 3 quarters · filed 2018-11-07 | -$1.59M 10-K · filed 2018-02-27 | |||
| 2017-09-30 | -$405.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$797.00K derived: sum of 2 quarters · filed 2018-11-07 | -$1.18M 10-Q · filed 2018-11-07 | -$1.52M derived: sum of 4 quarters · filed 2018-11-07 | |||
| 2017-06-30 | -$392.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$771.00K 10-Q · filed 2018-08-07 | -$1.12M derived: sum of 3 quarters · filed 2018-08-07 | -$1.46M derived: sum of 4 quarters · filed 2018-08-07 | |||
| 2017-03-31 | -$379.00K 10-Q · filed 2018-05-07 | -$728.00K derived: sum of 2 quarters · filed 2018-05-07 | -$1.07M derived: sum of 3 quarters · filed 2018-05-07 | -$2.71M derived: sum of 4 quarters · filed 2018-05-07 | |||
| 2016-12-31 | -$349.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$688.00K derived: sum of 2 quarters · filed 2018-02-27 | -$2.33M derived: sum of 3 quarters · filed 2018-02-27 | -$2.82M 10-K · filed 2018-02-27 | |||
| 2016-09-30 | -$339.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$1.99M derived: sum of 2 quarters · filed 2017-11-08 | -$2.47M 10-Q · filed 2017-11-08 | -$2.93M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | -$1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$2.13M 10-Q · filed 2017-08-02 | -$2.59M derived: sum of 3 quarters · filed 2018-02-27 | -$3.04M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | -$488.00K 10-Q · filed 2017-05-03 | -$948.00K derived: sum of 2 quarters · filed 2018-02-27 | -$1.40M derived: sum of 3 quarters · filed 2018-02-27 | -$3.38M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | -$460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$910.00K derived: sum of 2 quarters · filed 2018-02-27 | -$2.90M derived: sum of 3 quarters · filed 2018-02-27 | -$3.29M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | -$450.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$2.44M derived: sum of 2 quarters · filed 2016-11-02 | -$2.83M 10-Q · filed 2016-11-02 | -$3.21M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$2.38M 10-Q · filed 2016-08-03 | -$2.75M derived: sum of 3 quarters · filed 2017-02-28 | -$3.12M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | -$396.00K 10-Q · filed 2016-05-04 | -$768.00K derived: sum of 2 quarters · filed 2017-02-28 | -$1.13M derived: sum of 3 quarters · filed 2017-02-28 | -$1.49M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | -$372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$736.00K derived: sum of 2 quarters · filed 2017-02-28 | -$1.09M derived: sum of 3 quarters · filed 2017-02-28 | -$1.44M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | -$364.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$719.00K derived: sum of 2 quarters · filed 2015-11-04 | -$1.07M 10-Q · filed 2015-11-04 | -$1.23M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | -$355.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$703.00K 10-Q · filed 2015-08-05 | -$866.00K derived: sum of 3 quarters · filed 2016-02-29 | -$1.02M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | -$348.00K 10-Q · filed 2015-05-06 | -$347.79K 10-Q · filed 2014-05-06 | -$511.00K derived: sum of 2 quarters · filed 2016-02-29 | -$670.00K derived: sum of 3 quarters · filed 2016-02-29 | -$825.00K derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | -$163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$322.00K derived: sum of 2 quarters · filed 2016-02-29 | -$477.00K derived: sum of 3 quarters · filed 2016-02-29 | -$629.00K 10-K · filed 2016-02-29 | -$628.77K 10-K · filed 2014-03-20 | ||
| 2013-09-30 | -$159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$314.00K derived: sum of 2 quarters · filed 2014-11-12 | -$466.00K 10-Q · filed 2014-11-12 | -$466.30K 10-Q · filed 2013-11-12 | -$604.31K derived: sum of 4 quarters · filed 2015-03-03 | ||
| 2013-06-30 | -$155.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$307.00K 10-Q · filed 2014-08-05 | -$445.31K derived: sum of 3 quarters · filed 2015-03-03 | ||||
| 2013-03-31 | -$152.00K 10-Q · filed 2014-05-06 | -$290.30K derived: sum of 2 quarters · filed 2015-03-03 | |||||
| 2012-12-31 | -$138.31K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | -$534.00K 10-K · filed 2015-03-03 | -$533.56K 10-K · filed 2014-03-20 | ||||
| 2012-09-30 | -$395.69K 10-Q · filed 2013-11-12 | ||||||
| 2011-12-31 | -$447.02K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |